StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Mallinckrodt (MNK) StrataGraft Designated as Regenerative Medicine Advanced Therapy by U.S. FDA
July 18, 2017 7:02 AM
Mallinckrodt plc (NYSE: MNK), today announced that StrataGraft® regenerative skin tissue is among the first products to be designated as ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Corporate News
FDA
Hot Corp. News
Hot FDA News
Management Comments
Next Articles
U.S. FDA Designates Mallinckrodt's StrataGraft® as Regenerative Medicine Advanced Therapy
July 18, 2017 7:00 AM
Einhorn's Greenlight Capital Losses 4% in Q2 as Bubble Basket Proves 'Frustrating'
July 17, 2017 11:01 AM
Greenlight Capital closed out Mallinckrodt MNK) short: Letter
July 17, 2017 10:33 AM
FTC Approves Sublicense for Synacthen Depot Submitted by Mallinckrodt ARD Inc. (MNK)
July 14, 2017 2:24 PM